Silymarin in combination with ATRA enhances apoptosis induction in human acute promyelocytic NB4 cells
Copyright © 2023 Elsevier Ltd. All rights reserved..
Although all-trans retinoic acid (ATRA) is an efficient pattern in acute promyelocytic leukemia (APL) therapy, further studies are required due to the extant clinical limitations of ATRA. It has been reported that Silymarin, an anti-cancer herbal substance extracted from milk thistle (Silybum marianum), is able to regulate apoptosis in various types of cancer cells through different mechanisms of action. This study investigated the apoptosis-inducing effect of Silymarin (SM) alone and in combination with ATRA on human acute promyelocytic NB4 cells. Examination using MTT assay indicated that SM treatment leads to growth inhibition in NB4 cells in a dose-dependent manner. The IC50 values of SM and ATRA were calculated 90 μM and 2 μM, respectively. Cell cycle analysis by flow cytometry revealed that a more increase in the sub-G1 phase (a sign of apoptosis) when cells were exposed to SM in combination with ATRA. The incidence of apoptosis was confirmed through Hoechst 33258 staining and Annexin V-FITC analysis. The results showed that Silymarin enhances ATRA-induced apoptosis. The flow cytometric analysis also indicated an enhancement in levels of ROS in the treated cells with both compounds. The real-time PCR illustrated that SM targets apoptosis by down-regulation in Survivin and Bcl-2 while up-regulation in Bax. The findings showed that the combination of the two compounds is more effective in the induction of apoptosis in NB4 cells. Molecular docking studies indicated that Sylibin, as a primary compound of the SM, binds to the BH3 domain of Bcl-2 and the BIR domain of Survivin with various affinities. Based on the findings, it seems that SM used alone and in combination with ATRA may be beneficial for inducing apoptosis in APL cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:228 |
|---|---|
| Enthalten in: |
Toxicon : official journal of the International Society on Toxinology - 228(2023) vom: 01. Juni, Seite 107127 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parsa, Leila [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5688UTC01R |
|---|
| Anmerkungen: |
Date Completed 08.05.2023 Date Revised 08.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.toxicon.2023.107127 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355888092 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355888092 | ||
| 003 | DE-627 | ||
| 005 | 20231226065310.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.toxicon.2023.107127 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355888092 | ||
| 035 | |a (NLM)37085055 | ||
| 035 | |a (PII)S0041-0101(23)00113-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Parsa, Leila |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Silymarin in combination with ATRA enhances apoptosis induction in human acute promyelocytic NB4 cells |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.05.2023 | ||
| 500 | |a Date Revised 08.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Although all-trans retinoic acid (ATRA) is an efficient pattern in acute promyelocytic leukemia (APL) therapy, further studies are required due to the extant clinical limitations of ATRA. It has been reported that Silymarin, an anti-cancer herbal substance extracted from milk thistle (Silybum marianum), is able to regulate apoptosis in various types of cancer cells through different mechanisms of action. This study investigated the apoptosis-inducing effect of Silymarin (SM) alone and in combination with ATRA on human acute promyelocytic NB4 cells. Examination using MTT assay indicated that SM treatment leads to growth inhibition in NB4 cells in a dose-dependent manner. The IC50 values of SM and ATRA were calculated 90 μM and 2 μM, respectively. Cell cycle analysis by flow cytometry revealed that a more increase in the sub-G1 phase (a sign of apoptosis) when cells were exposed to SM in combination with ATRA. The incidence of apoptosis was confirmed through Hoechst 33258 staining and Annexin V-FITC analysis. The results showed that Silymarin enhances ATRA-induced apoptosis. The flow cytometric analysis also indicated an enhancement in levels of ROS in the treated cells with both compounds. The real-time PCR illustrated that SM targets apoptosis by down-regulation in Survivin and Bcl-2 while up-regulation in Bax. The findings showed that the combination of the two compounds is more effective in the induction of apoptosis in NB4 cells. Molecular docking studies indicated that Sylibin, as a primary compound of the SM, binds to the BH3 domain of Bcl-2 and the BIR domain of Survivin with various affinities. Based on the findings, it seems that SM used alone and in combination with ATRA may be beneficial for inducing apoptosis in APL cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute promyelocytic leukemia | |
| 650 | 4 | |a Apoptosis | |
| 650 | 4 | |a Bcl-2 | |
| 650 | 4 | |a ROS | |
| 650 | 4 | |a Silymarin | |
| 650 | 4 | |a Survivin | |
| 650 | 7 | |a Survivin |2 NLM | |
| 650 | 7 | |a Silymarin |2 NLM | |
| 650 | 7 | |a Tretinoin |2 NLM | |
| 650 | 7 | |a 5688UTC01R |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-bcl-2 |2 NLM | |
| 700 | 1 | |a Motafakkerazad, Rouhollah |e verfasserin |4 aut | |
| 700 | 1 | |a Soheyli, Sarvin Taleb |e verfasserin |4 aut | |
| 700 | 1 | |a Haratian, Amin |e verfasserin |4 aut | |
| 700 | 1 | |a Kosari-Nasab, Morteza |e verfasserin |4 aut | |
| 700 | 1 | |a Mahdavi, Majid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Toxicon : official journal of the International Society on Toxinology |d 1964 |g 228(2023) vom: 01. Juni, Seite 107127 |w (DE-627)NLM00002371X |x 1879-3150 |7 nnns |
| 773 | 1 | 8 | |g volume:228 |g year:2023 |g day:01 |g month:06 |g pages:107127 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.toxicon.2023.107127 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 228 |j 2023 |b 01 |c 06 |h 107127 | ||